Sanjivani Paranteral Ltd does manufacturing and export of pharmaceutical productsBusiness Overview: Sanjivani Paranteral Ltd is a pharmaceutical company headquartered in Mumbai. It specializes in manufacturing and distribution of high-quality parenteral and oral solid products. It caters to major therapeutic areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported…
Sanjivani Paranteral Limited has published advertisements regarding its 32nd Annual General Meeting (AGM), scheduled for Wednesday, September 16, 2026, at 11:00 AM via video conferencing. Shareholders can access the AGM notice and annual report for the financial year ended March 31, 2026, on the company's website. Remote e-voting will be...
Sanjivani Paranteral Limited's Board approved its unaudited financial results for the first quarter ended June 30, 2026. The company announced standalone revenue from operations of ₹19.61 Cr, achieving a net profit of ₹2.30 Cr. On a consolidated basis, the company reported total revenue of ₹23.99 Cr and a net profit...
Sanjivani Parenteral has announced the financial results for the first quarter of FY27. The company reported a Total Income of ₹23.99 Cr, up 33.81% year-on-year. EBITDA surged 61.04% to ₹4.32 Cr, with margins improving to 18.01%. Net Profit rose 43.94% to ₹2.49 Cr, and EPS stood at ₹2.03. Management highlighted...
Sanjivani Paranteral released its investor presentation for the first quarter of FY27, showcasing a strong recovery. Consolidated revenue from operations grew to ₹23.84 crore, a 33.81% increase year-over-year. Profit after tax jumped 43.94% to ₹2.49 crore, with EBITDA at ₹4.32 crore (18.01% margin). Exports contributed ₹17.61 crore, demonstrating resilience after...
Sanjivani Paranteral Limited has informed about its Postal Ballot Notice and remote e-voting process for shareholder approval on key matters. The company seeks consent for issuing up to 5,00,000 convertible warrants on a preferential basis to a promoter entity. Additionally, shareholders will vote on significant related party transactions with its...
